15:00 EST 12 Feb 2014 | PR Web

Join Miami Stem Cell Treatment Center on an exciting educational seminar focusing on how adipose-derived stem cells have been shown to have a preferred differentiation capability, have a minimal and virtually painless ease of extraction, and have been scientifically proven to have strong immuno-modulatory effects.

Boca Raton, FL (PRWEB) February 12, 2014

The Miami Stem Cell Treatment Center, PC, located in Miami, Ft. Lauderdale, and Boca Raton, Florida, announces a series of free public seminars on the use of stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia Smyrniotis, Medical Director.

The seminars will be held on February 16th and March 2nd. On February 16th, the seminar will be held at the Marriott Boca Raton, at Boca Center, 5150 Town Center Circle, Boca Raton, Florida 33486, at 2pm; and on March 2nd at the Hampton Inn Fort Lauderdale Downtown, 250 N. Andrews Blvd., Fort Lauderdale, Florida 33301, at 2pm. You can also join Miami Stem Cell Treatment Center at the Health and Wellness Experience Expo presented by WPEC Channel 12 and the Sun-Sentinel on March 1st at Mizner Park Amphitheater, Boca Raton, Florida from 10am-5pm. No reservations required.

At the Miami Stem Cell Treatment Center, utilizing investigational protocols, adult adipose derived stem cells (ADSCs) can be deployed to improve patients quality of life with a number of degenerative conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (also called stromal vascular fraction (SVF)). Adipose tissue is exceptionally abundant in ADSCs. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys damaged cells. The Miami Stem Cell Treatment Center only uses autologous stem cells from a person's own fat no embryonic stem cells are used. Our current areas of study include: Heart Failure, Emphysema, COPD, Asthma, Parkinsons Disease, Stroke, Multiple Sclerosis, and orthopedic joint injections. For more information, or if someone thinks they may be a candidate for one of the stem cell protocols offered by Miami Stem Cell Treatment Center, they may contact Dr. Nia or Dr. Gionis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About Miami Stem Cell Treatment Center:

The Miami Stem Cell Treatment Center is an affiliate of the Irvine Stem Cell Treatment Center (Irvine, California) and the Cell Surgical Network (CSN). We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Research Protections; and the study is registered with http://www.Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information contact: Miami(at)MiamiStemCellsUSA(dot)com or visit our website: http://www.MiamiStemCellsUSA.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/February/2014/prweb11578607.htm

Follow this link:
Miami Stem Cell Treatment Center Educational Seminar ...

Recommendation and review posted by simmons

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine have discovered that a well-known protein has a new function: It acts in a biological circuit to determine whether an immature neural cell remains in a stem-like state or proceeds to become a functional neuron.

The findings, published in the February 13 online issue of Cell Reports, more fully illuminate a fundamental but still poorly understood cellular act and may have significant implications for future development of new therapies for specific neurological disorders, including autism and schizophrenia.

Postdoctoral fellow Chih-Hong Lou, working with principal investigator Miles F. Wilkinson, PhD, professor in the Department of Reproductive Medicine and a member of the UC San Diego Institute for Genomic Medicine, and other colleagues, discovered that this critical biological decision is controlled by UPF1, a protein essential for the nonsense-mediated RNA decay (NMD) pathway.

NMD was previously established to have two broad roles. First, it is a quality control mechanism used by cells to eliminate faulty messenger RNA (mRNA) molecules that help transcribe genetic information into the construction of proteins essential to life. Second, it degrades a specific group of normal mRNAs. The latter function of NMD has been hypothesized to be physiologically important, but until now it had not been clear whether this is the case.

Wilkinson and colleagues discovered that in concert with a special class of RNAs called microRNA, UPF1 acts as a molecular switch to determine when immature (non-functional) neural cells differentiate into non-dividing (functional) neurons. Specifically, UPF1 triggers the decay of a particular mRNA that encodes for a protein in the TGF- signaling pathway that promotes neural differentiation. By degrading that mRNA, the encoded protein fails to be produced and neural differentiation is prevented. Thus, Lou and colleagues identified for the first time a molecular circuit in which NMD acts to drive a normal biological response.

NMD also promotes the decay of mRNAs encoding proliferation inhibitors, which Wilkinson said may explain why NMD stimulates the proliferative state characteristic of stem cells.

There are many potential clinical ramifications for these findings, Wilkinson said. One is that by promoting the stem-like state, NMD may be useful for reprogramming differentiated cells into stem cells more efficiently.

Another implication follows from the finding that NMD is vital to the normal development of the brain in diverse species, including humans. Humans with deficiencies in NMD have intellectual disability and often also have schizophrenia and autism. Therapies to enhance NMD in affected individuals could be useful in restoring the correct balance of stem cells and differentiated neurons and thereby help restore normal brain function.

View original post here:
Protein Switch Dictates Cellular Fate: Stem Cell or Neuron

Recommendation and review posted by simmons

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Part 3: Regenerative Therapies: Prolotherapy, Platelet Rich Plasma (PRP) and Stem Cell Therapy Dr. David Wang, Harvard trained and Board Certified in Physica...

By: KaplanCenter

Read the original post:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video

Recommendation and review posted by simmons

CHICAGO -

The most dangerous heart attack is known as a STEMI. Its when the artery in the heart completely blocks blood flow.

Every minute counts when it comes to surviving a STEMI. Now, a patients own stem cells could hold the key to recovery.

Branko Koscak is making healthier choices after suffering a massive heart attack. Working 18 hour days had finally caught up with him.

"Just running all day, pretty much day and night," Koscak said.

Dr. Gary Schaer, a cardiologist, said the damage done by Koscak's nearly 100 percent blocked artery was life-threatening.

"Whole areas of the heart muscle had been severely injured by the heart attack," said Schaer, director of cardiology research, Rush University Medical Center.

Schaer is testing a new technique using a patient's own stem cells.

"This is the most exciting area of medicine that I've been involved in, in my 30 years or so of practice," Schaer explained.

A week after Koscak's heart attack, a catheter was placed into his previously blocked artery, and stem cells from his bone marrow were infused.

Excerpt from:
Health Beat: Fixing the heart with stem cells | Health ...

Recommendation and review posted by Bethany Smith

Baltimore

A new method of creating versatile stem cells from a relatively simple manipulation of existing cells could further reduce the need for any stem-cell research involving human embryos, according to leading ethicists.

Although the process has only been tested in mice, two studies published Jan. 29 in the journal Nature detailed research showing success with a process called stimulus-triggered acquisition of pluripotency, or STAP.

Scientists from Japan's RIKEN research institute and Harvard's Brigham and Women's Hospital in Boston were able to reprogram blood cells from newborn mice by placing them in a low-level acidic bath for 30 minutes. Seven to 9 percent of the cells subjected to such stress returned to a state of pluripotency and were able to grow into other types of cells in the body.

"If this technology proves feasible with human cells, which seems likely, it will offer yet another alternative for obtaining highly flexible stem cells without relying on the destructive use of human embryos," said Fr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center in Philadelphia. "This is clearly a positive direction for scientific research."

Pacholczyk, a priest of the diocese of Fall River, Mass., who holds a doctorate in neuroscience from Yale University, said the only "potential future ethical issue" raised by the new STAP cells would be if scientists were to coax them into "a new degree of flexibility beyond classical pluripotency," creating cells "with essential characteristics of embryos and the propensity to develop into the adult organism."

"Generating human embryos in the laboratory, regardless of the specific methodology, will always raise significant ethical red flags," he said.

The Catholic church opposes any research involving the destruction of human embryos to create stem cells.

Richard Doerflinger, associate director of the U.S. bishops' Secretariat for Pro-Life Activities, said if the new method were used to create stem cells so versatile that they could form placenta tissue and make human cloning easier, "then we would have serious moral problems with that." But there is no indication so far that the scientists could or would do so, he added.

"You could misuse any powerful technology, but the technique itself is not problematic" in terms of Catholic teaching, Doerflinger said.

Excerpt from:
New stem-cell method offers another alternative to embryonic research

Recommendation and review posted by Bethany Smith

By Marsha Bonhart Published: Wednesday, February 12, 2014, 6:05 pm Related Content

DAYTON, Ohio (WDTN) Longtime NBC News anchor Tom Brokaw announced Tuesday that he has cancer, but doctors say his chances of beating it are good.

Brokaw has multiple myeloma, a cancer affecting blood cells in the bone marrow.

A cancer or leukemia starts with the white cell count called plasma cells overpopulating. It can cause destruction of the bone, said Dr. Burhan Yanes, Miami Valley Hospital.

Normally, healthy bone would show solid in an x-ray. A bone damaged by multiple myeloma is spongy, with holes.

Then they could break. Thats the problem, you can break a bone, break your back and be paralyzed.

The disorder can also cause severe anemia and kidney damage.

There is no cure, but treatment, Dr. Yanes says, can extend life for a decade or more.

The standard treatment for anyone younger, less than age 65, we do chemo induction and after that we do high dose chemo and stem cell transplant.

The aggressive transplant for an older person like the 74 year old Tom Brokaw is risky.

Continue reading here:
Brokaw cancer is treatable, but not curable

Recommendation and review posted by Bethany Smith

Thursday 13 February 2014

Skin reactions during radiation therapy preventable: new finding

Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, a clinical trial shows.

Although many skincare products have been tested in clinical trials over the years, until now none have been able to completely prevent severe skin reactions, says senior lecturer Dr Patries Herst of University of Otago Wellingtons Department of Radiation Therapy.

Dr Herst and her team of radiation therapists, oncology nurses and medical physicists have completed five randomised controlled clinical trials in public hospitals in Dunedin, Wellington, Palmerston North and Auckland Radiation Oncology over the past five years, all focusing on side effects caused by radiation therapy.

Their most recent trial was a close collaboration with Dunedin Hospital, and demonstrated it is possible to prevent skin reactions from developing in breast cancer patients undergoing radiation therapy.

Skin reactions are common in these patients, ranging from mild redness to ulceration with symptoms of pain, burning and itchiness, Dr Herst says.

This can impact negatively on day-to-day life for patients who already have to cope with being diagnosed with and treated for cancer.

She is delighted with the results, and identification of a product that really works.

This is fantastic news for cancer patients and it has put New Zealand firmly on the world map as a leader in clinical research into radiation-induced acute side effects.

Follow this link:
Skin reactions during radiation therapy preventable

Recommendation and review posted by Bethany Smith

Severe skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of treatment, a clinical trial shows.

Although many skincare products have been tested in clinical trials over the years, until now none have been able to completely prevent severe skin reactions, says senior lecturer Dr Patries Herst of University of Otago Wellingtons Department of Radiation Therapy.

Dr Herst and her team of radiation therapists, oncology nurses and medical physicists have completed five randomised controlled clinical trials in public hospitals in Dunedin, Wellington, Palmerston North and Auckland Radiation Oncology over the past five years, all focusing on side effects caused by radiation therapy.

Their most recent trial was a close collaboration with Dunedin Hospital, and demonstrated it is possible to prevent skin reactions from developing in breast cancer patients undergoing radiation therapy.

Skin reactions are common in these patients, ranging from mild redness to ulceration with symptoms of pain, burning and itchiness, Dr Herst says.

"This can impact negatively on day-to-day life for patients who already have to cope with being diagnosed with and treated for cancer."

She is delighted with the results, and identification of a product that really works.

"This is fantastic news for cancer patients and it has put New Zealand firmly on the world map as a leader in clinical research into radiation-induced acute side effects."

The dressings work by adhering closely to the small folds in the skin without the use of adhesives, so do not stick to open wounds. By protecting the radiation-damaged skin from friction against items of clothing or other parts of the body, they allow the stem cells of the skin to heal from the radiation damage in an undisturbed environment. The dressings are also free of chemicals that could react with the skin.

Dr Herst is currently setting up a trial that will test the dressings in head and neck cancer patients.

See the original post:
Skin reactions during radiation therapy preventable - research

Recommendation and review posted by Bethany Smith

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Dr. David Wang, Harvard trained and Board Certified in Physical Medicine Rehabilitation, is an international leader in the growing field of Regenerative In...

By: KaplanCenter

More here:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video

Recommendation and review posted by Bethany Smith

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by potentially identifying individuals who might benefit from targeting the pre-leukemic stem cell. AML is an aggressive blood cancer that the new research shows starts in stem cells in the bone marrow. Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN), and Professor in the Department of Molecular Genetics, University of Toronto, pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007).

"Our discovery lays the groundwork to detect and target the pre-leukemic stem cell and thereby potentially stop the disease at a very early stage when it may be more amenable to treatment," says Dr. Dick, who holds a Canada Research Chair in Stem Cell Biology and is also Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research (OICR).

"Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the pre-leukemic stem cell to prevent relapse," he says.

The findings show that in about 25% of AML patients, a mutation in the gene DNMT3a causes pre-leukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

The discovery of pre-leukemic stem cells came out of a large Leukemia Disease Team that Dr. Dick assembled and included oncologists who collected samples for the Princess Margaret Cancer Centre Biobank and genome scientists at the OICR who developed sophisticated targeted sequencing methodology. With this team, it was possible to carry out genomic analysis of more than 100 leukemia genes on many patient samples. The findings also capitalized on data from more than six years of experiments in Dr. Dick's lab involving growing human AML in special mice that do not reject human cells.

"By peering into the black box of how cancer develops during the months and years prior to when it is first diagnosed, we have demonstrated a unique finding. People tend to think relapse after remission means chemotherapy didn't kill all the cancer cells. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the pre-leukemic stem cells that can trigger another round of AML development and ultimately disease relapse," says Dr. Dick, who anticipates the findings will spawn accelerated drug development to specifically target DNMT3a.

These findings should also provide impetus for researchers to look for pre-cancerous cells in AML patients with other mutations and even in non-blood cancers.

Dr. Dick is also renowned for isolating a human blood stem cell in its purest form (2011) -- as a single stem cell capable of regenerating the entire blood system. He is a Senior Scientist at UHN's McEwen Centre for Regenerative Medicine and co-leader of a Cancer Stem Cell Consortium (CSCC)-funded research project HALT (Highly Active Anti-Leukemia Stem Cell Therapy), which is a partnership between CSCC and the California Institute for Regenerative Medicine.

For more than 20 years, Dr. Dick's research has focused on understanding the cellular processes that maintain tumour growth by investigating the complexities and interplay among genetic and non-genetic determinants of cancer. His research follows on the original 1961 discovery of the blood stem cell by Princess Margaret Cancer Centre (formerly Ontario Cancer Institute) scientists Dr. James Till and the late Dr. Ernest McCulloch, which formed the basis of all current stem cell research.

The rest is here:
Cancer Researchers Discover Pre-Leukemic Stem Cell at Root of AML, Relapse

Recommendation and review posted by Bethany Smith

Poway, California (PRWEB) February 13, 2014

The leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., and Americas best-loved pet insurer, Petplan, are working together to bring stem cell therapy and other regenerative cell therapies to pets nationwide. Stem cell therapy by Vet-Stem has been available for pets like dogs and cats for the last decade and covered by Petplan since 2010.

Founded in 2003 by Chris and Natasha Ashton, Petplan was recently named to Forbes magazines annual ranking of Americas Most Promising Companies for the second year in a row, and is rated one of the top pet insurance companies by Consumer Advocate and Canine Journal. Petplan proudly offers life-long coverage for hereditary and chronic conditions as well as alternative treatments, like stem cell therapy, as standard.

Our core value is that pets come first, and that starts with our comprehensive plans. So, were excited to see so many of our policyholders start to take advantage of cutting-edge treatments like Vet-Stem Regenerative Cell Therapy. Our team thrives on being able to provide coverage for the best and most up-to-date treatment modalities for the pets in our Petplan family, so hearing great stories about stem cell therapy from our policyholders is a real boost for us! - Dr. Jules Benson, Vice President of Veterinary Services at Petplan

Current uses of stem cell therapy are treating the pain and inflammation from arthritis and to repair orthopedic injuries. According to veterinarians, greater than 80% of dogs showed an improved quality of life after stem cell therapy. At 90 days post-treatment, more than 33% of dogs discontinued use of non-steroidal anti-inflammatory drugs (NSAIDs) completely, with an additional 28% decreasing their usage.

I started Vet-Stem in order to help horses with career-ending injuries to their tendons and ligaments, but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced, as well as contributing to changes in human medicine, - Robert Harman, DVM, CEO, Vet-Stem, Inc.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read more:
Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets

Recommendation and review posted by Bethany Smith

TUESDAY, Feb. 11, 2014 (HealthDay News) -- Predicting whether early stage breast cancer will become invasive and lethal remains a challenge for doctors. But new research suggests that a panel of 55 genes might help guide medical odds-makers.

Women who had genetic alterations in this panel were less likely to survive breast cancer over nearly two decades of follow-up than those without any changes, said study researcher Susette Mueller, professor emeritus of oncology at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, D.C.

"If people had changes in any of the 55 genes, they had worse outcomes," she said.

Researchers studying this panel focused on the loss of a powerful tumor suppressor gene known as SYK. When a copy of SYK is lost, 51 other genes are directly affected. This leads to genetic disruption, according to the authors of the study, published online Feb. 11 in PLOS ONE.

The gene screen is far from ready for use in everyday practice, Mueller noted. But it's hoped that more research will show it's a reliable tool, one that might guide doctors making treatment decisions.

"When women have ductal carcinoma in situ (DCIS), it's carcinoma but not invasive," Mueller said. "A small number of them go on to have invasive cancer."

But there is no accurate way to determine which ones will progress and which won't.

How abnormalities in genes might trigger a cancer, predict its progression and help determine the best treatment is the subject of numerous investigations.

For several years, experts have recognized SYK as an inhibitor of breast cancer cell growth and spread. SYK can be lost when a gene is "turned off," Mueller said, or when genetic instability occurs because pieces of DNA are missing, for instance.

In the current study, funded by Georgetown Lombardi and the U.S. Public Health Service, Mueller examined tissue samples from 19 women diagnosed with breast cancer. Eight of the women had ductal carcinoma in situ -- noninvasive cancer, she said. The others also had some cancer in adjacent tissue.

Continued here:
Gene Exam Might Predict Breast Cancer Progression - US News

Recommendation and review posted by Bethany Smith

Houston, Texas (PRWEB) February 12, 2014

Gene by Gene, Ltd., a Houston-based genetic testing company for health and ancestry research, announced today that their genetic testing laboratory is now CAP accredited. The accreditation was based on a recent on-site visit by CAP inspectors and a detailed review of staff qualifications, facilities, laboratory records, protocols and quality control procedures.

Gene by Gene joins an elite group of laboratories worldwide that meet the highest standards of care and quality control. The U.S. federal government recognizes the CAP accreditation program as being equal-to or more-stringent-than the governments own inspection program.

Gene by Gene has offered genetic testing since 2000 and the accreditation of our laboratory by the College of American Pathologists marks an important milestone in our mission to deliver state-of-the-art genetic testing to consumers, researchers, and physicians, said Max Blankfeld, Chief Operating Officer at Gene by Gene, Ltd.

About Gene by Gene, Ltd. Founded in 2000, Gene By Gene, Ltd. (http://www.genebygene.com) is a CAP-accredited and CLIA-registered genetic testing company that serves consumers, researchers, and physicians. Gene by Gene offers a wide range of regulated clinical diagnostic tests, as well as research use only (RUO) tests. The Family Tree DNA division (http://www.familytreeDNA.com) of Gene by Gene is a pioneer and leader in DNA testing for genealogy and ancestry. The company operates the largest genetic genealogy database in the world and has provided more than 5 million discrete genetic tests. Gene by Gene is privately held and headquartered in Houston, Texas.

About the College of American Pathologists The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the worlds largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care.

The rest is here:
Gene by Gene Receives Accreditation from the College of American Pathologists

Recommendation and review posted by Bethany Smith

Genetic Engineering Maximum Ride Style
Abigail Rasch #39;s "Science in Fiction" Video Contest submission ( can also be viewed here: https://www.wevideo.com/view/151007082)

By: Kavli "Science in Fiction" Video Channel

Visit link:
Genetic Engineering Maximum Ride Style - Video

Recommendation and review posted by Bethany Smith

Feature Article of Thursday, 13 February 2014

Columnist: Agorsor, Yafetto, Otwe, Galyuon

Israel D. K. Agorsor, Levi Yafetto, Emmanuel P. Otwe and Isaac K. A. Galyuon

1. Introduction

At the turn of the last decade, Ghana signaled its intention to adopt plant genetic engineering as part of the efforts towards modernizing its agriculture when it established the National Biosafety Committee. This committee would, among others, activate the processes for the formulation of a Biosafety Bill. In 2011, a draft Biosafety Bill was passed into law by Ghanas Parliament, and is known as Biosafety Act 2011 or Act 831. Genetic engineering techniques enable scientists to modify the genetic make-up of an organism, otherwise known as its genome, by inserting into the genome pieces of deoxyribonucleic acid (DNA) ? the genetic material ? that condition specific desirable traits from other organisms. These modifications result in what are known as genetically modified organisms (GMOs) or transgenic organisms (transgenics).

To say that the debates on GMOs are, perhaps, the fiercest of all debates that have ever engulfed any human endeavour and, for that matter, any scientific discipline in living memory may be an understatement. Why the GMO wars have been so fiercely fought is clear only to the extent that people and cultures have significant emotional attachment to food and food products, and thus anything that appears an aberration to these would always be fiercely resisted. However, the evidence, as we have it, is that these debates have at times gone beyond the science, and have assumed moral and speculative dimensions. The result is that quite often, moral questions are also asked to proponents of genetic engineering, questions whose answers may not be readily available.

Some of these moral questions include: Are scientists now playing God? Why do scientists interfere in nature and the natural order? Speculative ones include the myriad of diseases, such as cancer, heart diseases, diabetes and fibroid, that genetically modified (GM) food causes. Of course we are aware of some published reports which suggest GM foods could have adverse effects on human and animal health. But we are also aware that some of these reports have either been challenged or retracted from the scientific journals in which they were published after follow-up studies showed that the experiments leading to those conclusions were flawed. You may read, for example, Sralini affair at http://en.wikipedia.org/wiki/S%C3%A9ralini_affair, as well as the widely-referenced Pusztai study which although hailed by some scientists, has been challenged by others including the UK Royal Society. See the Pusztai affair at http://en.wikipedia.org/wiki/Pusztai_affair.

We have noticed, too, that in an opinion piece that appeared in the Daily Graphic of Monday, December 23, 2013, and titled GM Foods: Mass genocide, studies by Australian scientist Judy Carman and her colleague Jack Heinemann have been cited as evidence of health risks of GMOs. In fact, Carman and co-authors studies have been disputed. Many scientists, including the food regulator for Australia/New Zealand known as Food Standards Australia and New Zealand (FSANZ) have rejected Carman and colleagues claim that GM foods have health risks as reported in one study. See FSANZs response to Carman and colleagues claims at http://www.foodstandards.gov.au/consumer/gmfood/Pages/Response-to-Dr-Carman's-study.aspx. Basically, the charge is that it was flawed science that led to their claims.

For an example of a publication that discusses the health implications of GM foods, see the article (not an original research paper, but a review article) Health risks of genetically modified foods by Dona and Arvanitoyannis published in the journal Critical Reviews in Food Science and Nutrition in 2009 (Crit Rev Food Sci Nutr 49(2): 164-175) at http://www.ncbi.nlm.nih.gov/pubmed/18989835 (click on View full text). For a challenge to the views expressed in Dona and Arvanitoyannis, see the article Response to Health risks of genetically modified foods by Craig Rickard in the same journal at http://www.tandfonline.com/doi/full/10.1080/10408390903467787#tabModule.

Unfortunately, the independence of the authors of some of the pro- and anti-GMO articles and research papers have been questioned at times; the authors have been accused of doing the bidding of either biotechnology giants or anti-GMO movements because they have been receiving, allegedly, research funding from these groups. These accusations have also added to the complexity of the GMO debates.

Read more:
Ghanas GMO debates: beyond the sticking points (1)

Recommendation and review posted by Bethany Smith

PARIS, Feb 13 (BERNAMA-NNN-PRENSA LATINA) -- French company Abivax and the Centre for Genetic Engineering and Biotechnology (CIGB) in Cuba announced an agreement here Wednesday to partner in the development and commercialisation of vaccines with one against the Hepatitis B virus.

The CIGB, Cuba's leading biotechnology institution, has more than 50 research-development projects, while Abivax, based in Paris, is a product of the merger of the Wittycell, Splicos and Zophis firms. Their objective is to fight infectious diseases and cancer.

"Cuba is known for the excellence of its physicians and the quality of its vaccines. This is a project of international importance to put France foremost in this matter," Philippe Pouletty, president of the Administrative Council of the French firm, said.

Norkis Arteaga, head of Biocubafarma business department, said that the complementary nature of both companies in research and production will allow for the distribution of many products in the future.

Arteaga cited in a statement a licensing agreement between the CIGB and Abivax for the development and commercialisation of the therapeutic vaccine against Hepatitis B.

Cuba will provide the clinical results and capacity, while the French firm financial resources to complete other clinical trials in Europe and Asia along with the experience to register it in these markets and commercialise it later.

-- BERNAMA-NNN-PRENSA LATINA

See more here:
Cuba, France Agree To Develop Hepatitis B Vaccine

Recommendation and review posted by Bethany Smith

by Mark Derewicz

(Medical Xpress)Put yourself in the shoes of a psychiatrist. You just diagnosed a person with schizophrenia, and you can prescribe any number of antipsychotic drugs, all of which can cause serious side effects. You know that older drugs, such as haloperidol, work well, but a third of all schizophrenia patients who take it suffer from Parkinsonian-like symptoms, such as tremors, involuntary spasms, and uncontrollable facial movements. You also know that those side effects are permanent in about half the people who experience them. In other words, you could be prescribed a drug that causes permanent brain damage.

So you consider prescribing a newer drug, such as clozapine, which also helps a large portion of patients. But clozapine causes severe weight gain and diabetes in many people. You check your patient's history. He smokes, as do 90 percent of people diagnosed with schizophrenia. He weighs a lot for his height. Taking clozapine will substantially increase his risk of heart disease, and the drug costs much more than haloperidol. Your patient can't afford it.

Choosing the right drug is difficult, but you have to choose one. Letting the patient go without medication is not an option; untreated schizophrenia is much worse than even the most serious side effects.

What do you do?

You know what you'd like to do: run a blood test to figure out your patient's genetic susceptibility to the permanent side effects of haloperidol. But that genetic screen doesn't exist. In fact, the genetic underpinnings of drug side effects, in general, are not well understood.

Researchers at the UNC School of Medicine are trying to change that.

Two labs headed by statistical geneticist William Valdar, PhD, and psychiatric geneticist Patrick Sullivan, MD, have developed a new statistical model that scientists can use to parse the complex genetics of side effect susceptibility.

In a paper featured in the journal Genetics, their teams describe how they've begun to strip away the mystery behind haloperidol. Their findings represent the first quantitative description of the genetic architecture of haloperidol response.

Genetic smoke screen

Excerpt from:
The genetics of drug tolerance

Recommendation and review posted by Bethany Smith

Researchers at the UNC School of Medicine conducted a comprehensive genetic analysis of invasive bladder cancer tumors to discover that the disease shares genetic similarities with two forms of breast cancer. The finding is significant because a greater understanding of the genetic basis of cancers, such as breast cancers, has in the recent past led to the development of new therapies and diagnostic aids.

Bladder cancer, which is the fourth most common malignancy in men and ninth in women in the United States, claimed more than 15,000 lives last year.

The analysis of 262 bladder cancer tumors, published online in the Proceedings of the National Academy of Sciences, revealed that the invasive form of the disease can be classified into two distinct genetic subtypes -- basal-like and luminal -- which were shown to be highly similar to the basal and luminal subtypes of breast cancer first described by Charles Perou, PhD, the May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger.

"It will be particularly interesting to see whether the bladder subtypes, like the breast subtypes, are useful in stratification for therapy," said lead author William Kim, MD, a researcher at the UNC Lineberger Comprehensive Cancer Center and associate professor in the departments of genetics and medicine at UNC.

Mapping genetic signaling pathways of breast cancer subtypes has led to the development of drugs to treat patients and diagnostic aids that help physicians determine the best course of therapy for patients. Because the identified bladder cancer subtypes share many of the same genetic signaling pathways of breast cancer, researchers hope that the identification of the genetic subtypes can lead to similar advances.

"Currently there are no approved targeted therapies for bladder cancer," said lead author Jeffrey Damrauer, graduate student in the Curriculum of Genetics and Molecular Biology at the UNC School of Medicine. "Our hope is that the identification of these subtypes will aid in the discovery of targetable pathways that will advance bladder cancer treatment."

The study also revealed a possible answer to why women diagnosed with bladder cancer have overall poorer outcomes compared to males. Analysis showed that female patients had a significantly higher incidence of the deadlier basal-like tumors. But researchers said that more research is needed before a definite link between the subtype and survival rate can be confirmed.

Dr. Kim's lab has developed a gene map -- BASE47 -- that proved successful as a prognostic aid when applied to the tumor samples in the study. The PAM50 genetic test, a similar genetic map developed in the Perou lab, was recently approved as a clinical diagnostic tool by the FDA.

Story Source:

The above story is based on materials provided by University of North Carolina Health Care. Note: Materials may be edited for content and length.

Read the original post:
Potential route to bladder cancer diagnostics, treatments

Recommendation and review posted by Bethany Smith

Attack Of The B-Team - Episode 6 - Advanced Genetics
Leave a like if you want to see more Attack Of The B-Team! DESCRIPTION Join me as I undertake the most epic quest of evilness, into the new mod pack brought ...

By: WTFG33ks

Read more:
Attack Of The B-Team - Episode 6 - Advanced Genetics - Video

Recommendation and review posted by Bethany Smith

Minecraft Mod: Advanced Genetics
Sean takes a look at a mod that allows you to get the the powers and abilities from minecraft mobs. Anything from Ender Dragons, Endermen, Wither Skeletons, ...

By: Blurb Gaming

View original post here:
Minecraft Mod: Advanced Genetics - Video

Recommendation and review posted by Bethany Smith

Genetics With a Smile - Tutorial
Video tutorial for the Smiley Face Genetics Lab.

By: Ingle Larkin

Excerpt from:
Genetics With a Smile - Tutorial - Video

Recommendation and review posted by Bethany Smith

Genetics and the Punnett Square
Video to introduce how to use a Punnett square for mono hybrid crosses as prep for class work. My first attempt at flipping my middle school science classroom.

By: Bucky #39;s Science Channel

Continued here:
Genetics and the Punnett Square - Video

Recommendation and review posted by Bethany Smith

By a News Reporter-Staff News Editor at Diabetes Week -- He is one of eight UC San Diego researchers to receive a combined total of $8.165 million in funding from the California Institute for Regenerative Medicine in a new round of Basic Biology awards announced Jan. 29. Metallo's share is $1.124 million over three years. The awards were made by CIRM's Independent Citizens Oversight Committee (see also Stem Cells).

Heart cells are unique in that they must expend a tremendous amount of energy in order for the heart to function properly, generating the mechanical forces necessary to pump blood through the body, Metallo said. Therefore, it is important that heart cells generated from stem cells in the lab eat the right foods. His research is focused on understanding cell metabolism - how cells convert carbohydrates, fat, and protein into fuel - and how disruptions in these processes contribute to diseases such as cancer, diabetes and obesity.

Metallo joined the Jacobs School of Engineering in 2011 after completing a postdoctoral fellowship on the metabolism of cancer cells at the Massachusetts Institute of Technology. His research there changed our understanding of how cells convert carbohydrates and protein (amino acids) to fat, a process which was thought to have been settled science for more than 50 years. The study, which was published January 2012, in the journal Nature, means doctors could have new targets for therapeutic drugs designed to stop cancer cell growth. In recognition of this work, Metallo was named the Rita Schaffer Young Investigator in 2012, which is awarded each year by the Biomedical Engineering Society to stimulate the research career of a young bioengineer. Last year, he was one of 15 young investigators in the United States selected to be a 2013 Searle Scholar.

The eight CIRM Basic Biology Awards for UC San Diego faculty were:

Maike Sander, School of Medicine, Department of Pediatrics, was awarded $1.161 million

Christian Metallo, Bioengineering, Jacobs School of Engineering, awarded $1,124 million

Cornelis Murre, Biological Sciences, awarded $1.161 million

Wei Wang, Chemistry and Biochemistry, awarded $1.161 million

David Cheresh, School of Medicine, Department of Pathology, UC San Diego Moores Cancer Center, awarded $1.161 million

Miles Wilkinson, School of Medicine, Department of Reproductive Medicine, awarded $619,200

See the rest here:
Bioengineer studying stem cell diets to make better heart ...

Recommendation and review posted by simmons

Stem Cell Facelift | Face Rejuvenation | Fat Transfer to Face
Stem cell facelift patient from Eterna MD is extremely happy with the results after receiving treatment in Orlando. Visit our website to learn more at http:/...

By: Eterna MD Regenerative Medicine

View post:
Stem Cell Facelift | Face Rejuvenation | Fat Transfer to Face - Video

Recommendation and review posted by sam

Freeport, Bahamas (PRWEB) February 11, 2014

Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, announces the company will host a hard hat reception for conference attendees at their new facility in Freeport. The conference, titled Bridging the Gap: Research to Point of Care, brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner. Gold Sponsor Okyanos Heart Institute hosts a networking reception for conference attendees at their facility in Freeport on Friday, February 21st from 5:00 7:00 p.m. The company is calling the reception a hard hat reception metaphorically as the construction is not yet completed.

Chief Medical Officer Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and Chief Science Officer Leslie Miller, M.D., F.A.C.C. will host the reception, along with CEO Matthew Feshbach and offer tours of the commercial cath lab which will offer stem cell therapy to qualified patients with advanced coronary artery disease under the new laws and regulations in The Bahamas.

Douglas Hammond, president of STEMSO, states, STEMSO will continue to provide a proactive and positive voice for organizations and jurisdictions using adult stem cells for therapies and transplants. The Commonwealth of The Bahamas, and our Gold Sponsor Okyanos Heart Institute provide an excellent example of the results that can be brought about with realistic, modern and balanced regulations that serve the national economic interest, patient needs for life-saving medicine and the business advantages for commercialization and translation of adult stem cells.

The reception in our facility will showcase the capabilities in The Bahamas to deliver high quality healthcare to patients in need, says Walpole. It will also provide an informal forum for relevant discussion on bridging the gap between research and point of care between scientists, regulatory experts, clinicians and government officials, and help to address issues of paramount importance such as patient safety and effective tracking of progress once the patients return home. We are proud to host this reception at Okyanos Heart Institute.

Treating patients with adipose-derived stem and regenerative cells (ADRCs) is showing existing promise in clinical trials, states Leslie Miller, M.D., F.A.C.C. an investigator in more than eighty clinical trials for heart failure. The next step in delivering stem cells to patients outside of clinical trials is close. I am enormously excited about the opportunity with this conference to engage in meaningful discussion around what parameters must exist to treat heart failure patients safely and tracking the effectiveness of these new options, which previously were unavailable to patients who have had heart attacks and/or stents, and who continue to worsen after exhausting all other interventions available to them.

The complete agenda for the conference can be found on STEMSOs website at http://www.stemso.org. Other speakers include stem cell researchers, scientists and practitioners from around the world with leading discoveries in the field, and investors in the healthcare space.

Registration is open for attending and exhibiting on STEMSOs website.

About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (Oceanos) symbolizes flow. For more information, go to http://www.okyanos.com.

Okyanos LinkedIn Page: http://www.linkedin.com/company/okyanos-heart-institute Okyanos Facebook Page: https://www.facebook.com/OKYANOS Okyanos Twitter Page: https://twitter.com/#!/OkyanosHeart Okyanos Google+ Page: https://plus.google.com/+Okyanos/posts Okyanos You Tube Physician Channel: http://www.youtube.com/user/okyanosforphysicians

Visit link:
Okyanos Heart Institute Hosts Networking Reception for the ...

Recommendation and review posted by Bethany Smith